Literature DB >> 6139122

Effects of beta 1-adrenoceptor agonism on plasma renin activity in normal men.

J Staessen, A Cattaert, A De Schaepdryver, R Fagard, P Lijnen, E Moerman, A Amery.   

Abstract

The contribution of beta 1-adrenoceptors to the regulation of plasma renin activity was investigated in nine healthy sodium-replete volunteers: seven subjects received a cumulative intravenous dose of 75 micrograms/kg prenalterol, a predominant beta 1-adrenoceptor agonist, and two subjects only vehiculum. In the seven actively treated subjects beta 1-adrenoceptor agonism increased (P less than 0.001) systolic intra-arterial pressure by an average of 16 +/- 4 mm Hg and heart rate by 19 +/- 3 beats min. These increases were significantly (P less than 0.04) different from the changes observed in the two control subjects (+ 3 +/- 4 mm Hg and -1 +/- 4 beats/min, respectively). Plasma renin activity, however, tended to decrease in both the actively (-38%) and saline (-28%) treated subjects. Predominant beta 1-adrenoceptor agonism, powerful enough to increase systolic pressure and heart rate does not increase plasma renin activity in supine sodium-replete normal man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139122      PMCID: PMC1428074          DOI: 10.1111/j.1365-2125.1983.tb02215.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  A potent new beta2-adrenoceptor blocking agent.

Authors:  J L Imbs; F Miesch; J Schwartz; J Velly; G Leclerc; A Mann; C G Wermuth
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

2.  [Participation of beta 1- and beta 2-adrenergic receptors on the renin-liberation].

Authors:  K A Meurer; L Maxrath; A Helber; W Kaufmann
Journal:  Verh Dtsch Ges Inn Med       Date:  1976

3.  Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range.

Authors:  M Da Prada
Journal:  Life Sci       Date:  1976-10-15       Impact factor: 5.037

4.  Measurement of renin and substrate concentrations in human serum.

Authors:  A B Gould; S Goodman; R DeWolf; G Onesti; C Swartz
Journal:  Anal Biochem       Date:  1979-04-01       Impact factor: 3.365

5.  Effects of a beta 1-selective adrenergic agonist in normal human volunteers.

Authors:  K A Meurer; R Lang; V Hombach; A Helber
Journal:  Klin Wochenschr       Date:  1980-04-15

6.  The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise.

Authors:  P J Lijnen; A K Amery; R H Fagard; T M Reybrouck; E J Moerman; A F De Schaepdryver
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

7.  Plasma catecholamines in clinical investigation: a useful index or a meaningless number?

Authors:  E L Bravo; R C Tarazi
Journal:  J Lab Clin Med       Date:  1982-08

8.  Faster radioimmunoassay of angiotensin I at 37 degrees C.

Authors:  F Fyhrquist; L Puutula
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

9.  Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients.

Authors:  A Amery; L Billiet; A Boel; R Fagard; T Reybrouck; J Willems
Journal:  Am Heart J       Date:  1976-05       Impact factor: 4.749

10.  Comparison of the effects on renin release of beta adrenergic antagonists with differing properties.

Authors:  M A Weber; G S Stokes; J M Gain
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  2 in total

1.  Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system.

Authors:  S M Freudenthaler; T Schenck; I Lucht; C H Gleiter
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Metabolic and hormonal effects of preferential beta 1 and beta 2-adrenoceptor stimulation in man.

Authors:  C Tantucci; F Santeusanio; M Beschi; M Castellano; C Sorbini; V Grassi
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.